Author

D. Richard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Banerjee· 1 shared A. C. Doxey· 1 shared A. G. McArthur· 1 shared A. J. McGeer· 1 shared A. T. Irving· 1 shared B. J.- M. Tremblay· 1 shared B. Wang· 1 shared D. Kunke· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Banerjee

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response

P. Shahrouzi, Y. Azimzade, W. Brankiewicz, S. Bhatia, D. Kunke, D. Richard, X. Tekpli, V. N. Kristensen, P. H. G. Duijf

This study identifies the loss of chromosome 13q14.2 as a key driver of breast cancer pathogenesis and drug response, showing its impact on tumor survival, cell cycle, and treatment susceptibility.

bioRxiv · Jun 18, 2024Cancer Biology

Experimental and natural evidence of SARS-CoV-2 infection-induced activation of type I interferon responses

A. Banerjee, N. El-Sayes, P. Budylowski, D. Richard, H. Maan, J. Aguiar, K. Baid, M. R. D'Agostino, J. C. Ang, B. J.- M. Tremblay, S. Afkhami, M. Karimzadeh, A. T. Irving, L. Yip, M. A. Ostrowski, , K. Mossman

This study shows SARS-CoV-2 infection induces a mild type I IFN response in vitro and in moderate COVID-19 cases, and cannot inhibit exogenous IFN induction.

bioRxiv · Jun 18, 2020Immunology